1160293-25-3

Usage

Uses

Used in Pharmaceutical Industry:
1-(2-chloroacetyl)-2-oxo-2,3-dihydro-1H-indole-6-carboxylic acid methyl ester is used as a potential pharmaceutical compound for its possible biological activity. The indole ring and chloroacetyl group in its structure may contribute to its therapeutic effects, although the specific applications and mechanisms of action need to be further investigated.
Used in Drug Formulation:
In the pharmaceutical industry, 1-(2-chloroacetyl)-2-oxo-2,3-dihydro-1H-indole-6-carboxylic acid methyl ester is used to improve the solubility of drugs in organic solvents. The methyl ester group enhances the compound's solubility, which can be beneficial for the development of pharmaceutical formulations with better bioavailability and drug delivery.

Upstream product

• 14192-26-8 2-oxo-2,3-dihydro-1H-indole-6-carboxylic acid methyl ester 
• 79-04-9 chloroacetyl chloride 
• 541-88-8 Chloroacetic anhydride 
• 96-99-1 4-chloro-3-nitrobenzoate 
• 1160293-27-5 [4-(methoxycarbonyl)-2-nitrophenyl]malonic acid dimethyl ester 
• 14719-83-6 methyl 3-nitro-4-chlorobenzoate 
• 618-95-1 methyl 3-nitrobenzoate 
• 121-92-6 3-nitrobenzoic acid 
• 334952-07-7 4-methoxycarbonylmethyl-3-nitrobenzoic acid methyl ester 
• 199328-10-4 methyl 2-oxoindoline-5-carboxylate 

Downstream Products

• 1160293-24-2 N-chloroacetyl-3-[methoxy(phenyl)methylene]-2-oxoindoline-6-carboxylic acid methyl ester 
• 656247-18-6 methyl (3Z)-3-[({4-[N-methyl-2-(4-methylpiperazin-1-yl)acetamido]phenyl}amino)(phenyl)methylidene]-2-oxo-2,3-dihydro-1H-indole-6-carboxylate ethanesulfonate salt 
• 1160293-22-0 3-[methoxy(phenyl)methylene]-2-oxoindoline-6-carboxylic acid methyl ester 
• 1987887-92-2 methyl (Z)-3-(((4-(methylamino)phenyl)amino)(phenyl)methylene)-2-oxoindoline-6-carboxylate 

Relevant academic research and scientific papers

Indolone derivative and pharmaceutical application thereof

The invention provides an indolone derivative and pharmaceutical application thereof. The structure of the indolone derivative is shown as a formula (A). Experimental results show that the compound provided by the invention has obviously improved pharmacokinetic properties than BIBF1120, has excellent inhibition effects on VEGFR, FGFR and PDGFR, can be used as a VEGFR, FGFR and/or PDGFR inhibitor,an angiogenesis inhibitor and a drug for preventing and/or treating various tumors including pharyngeal squamous cell carcinoma, and has a wide application prospect.

Substituted indolinone derivative and application thereof

The invention relates to a substituted indolinone derivative represented as the general formula (I) and used as a tyrosine kinase inhibitor, and medicinal acceptable salts or isomers thereof, wherein the R1, R2, R3, R4, R5, R6, R7, n and the ring A are defined as the specifications. The invention also relates to a preparation method of the compound, and an application of the compound in preparation of medicines for prevention or therapy of fibrosis diseases and excess hyperplasia diseases.

Novel 6-methoxycarbonyl indolinones bearing a pyrrole Mannich base moiety as angiokinase inhibitors

Inhibition of tumor angiogenesis through simultaneously disturbing vascular endothelial growth factor (VEGF) and platelet-derived growth factor (PDGF) mediated signaling pathways is a well-established approach in intervention of tumor. A series of 6-methoxycarbonyl indolinones bearing a pyrrole Mannich base moiety were synthesized and evaluated as potent angiokinase inhibitors. Compound 8a demonstrated favorable enzymatic activity against all subtypes of VEGFR and PDGFR. Also, it potently suppressed proliferation of HT-29 cells by inducing apoptosis. Compound 8a has emerged as a promising lead compound for development of angiokinase inhibitors targeting VEGFR and PDGFR.

nepal reaches Neeb process and intermediates for the synthesis of (by machine translation)

The invention discloses a method for synthesizing nepal reaches Neeb and intermediates thereof, the synthesis method comprises: under acidic conditions, the compound of formula (II) reaction of a compound of the formula (I) compound of formula (III); compound (III) of the detached with acid uncle Ding Zhiji carbonate, adding alkali reaction of the compound of formula (V); the compound of formula (V) reaction with chloroacetic acid derivatives of formula (VI) the activation of the compound, then the reaction-methyl piperazine N, obtain nepal reaches Neeb. The present invention provides a mild reaction conditions of a new method for synthesizing nepal reaches Neeb, the invention also provides synthetic intermediates nepal reaches Neeb. (by machine translation)

Preparation method of crystalline nintedanib esylate

The invention discloses a preparation method of crystalline nintedanib esylate (3-Z-[1-(4-(N-((4-methyl-piperazin-1-yl)-methylcarbonyl)-N-methyl-amino)-phenylamino)-1-phenyl-methylene]-6-methoxycarbonyl-2-dihydroindolone monoethyl sulfonate). The method comprises steps as follows: (1) a compound represented in the formula (B) and acylating chlorination reagent chloroacetic anhydride react, and acyl chloride (C) is obtained; (2) the compound represented in the formula (C) and trimethyl orthobenzoate have a condensation reaction, and a compound represented in the formula (D) is obtained; (3) the compound represented in the formula (D) is deprotected, and a compound represented in the formula (E) is obtained; (4) the compound represented in the formula (E) and N-(4-aminophenyl)-N-methyl-2-(4-methylpiperazin-1-yl) acetamide have a condensation reaction, and a compound represented in the formula (F) is obtained; (5) the compound represented in the formula (F) and ethanesulfonic acid have a salification reaction, and a nintedanib esylate compound represented in the formula (A) is obtained. The stable crystalline nintedanib esylate can be obtained with the method, technological conditions are mild, aftertreatment is simple, the purity is high, the reaction cost is low, and industrial production is easy to realize.

Design, synthesis and biological evaluation of deuterated nintedanib for improving pharmacokinetic properties

Nintedanib is a novel triple angiokinase inhibitor that inhibits three growth factors simultaneously. Deuterated derivatives of nintedanib at certain metabolically active sites were prepared and evaluated in vitro and in vivo. In particular, deuterated compound SKLB-C2202 had significantly improved pharmacokinetic properties compared with nintedanib. These efforts lay the foundation for further investigating the druggability of SKLB-C2202. Deuterated derivatives of nintedanib at certain metabolically active sites were prepared and evaluated in vitro and in vivo. Deuterated compound SKLB-C2202 had significantly improved pharmacokinetic properties compared with nintedanib. Further research is underway.

INTEDANIB SALTS AND SOLID STATE FORMS THEREOF

The present invention provides salts of Intedanib, crystalline forms of the salts of Intedanib, processes for their manufacture and their use in pharmaceutical compositions.

INDOLINONE DERIVATIVES AND PROCESS FOR THEIR MANUFACTURE

The present invention relates to specific indolinone derivatives, namely the compounds of formula, in which R1 represents an hydrogen atom or a group, and R2 and R3 each represent an hydrogen atom or R2 and R3 taken together represent a group, with the proviso that when R1 represents an hydrogen atom R2 and R3 taken together represent a group, and to a process for their manufacture.

PROCESS FOR THE MANUFACTURE OF AN INDOLINONE DERIVATIVE

The present invention relates to a process for the manufacture of a specific indolinone derivative and a pharmaceutically acceptable salt thereof, namely 3-Z-[1-(4-(N-((4-methyl-piperazin-1-yl)-methylcarbonyl)-N-methyl-amino)-anilino)-1-phenyl-methylene]-6-methoxycarbonyl-2-indolinone and its monoethanesulfonate, to new manufacturing steps and to new intermediates of this process.